AstraZeneca Plc (LON:AZN) reported on Friday that as on 31 October 2019, the company's issued share capital with voting rights is 1,311,904,600 ordinary shares of USD0.25.

Also, no shares are held in treasury.

As a result, the total number of voting rights in AstraZeneca is 1,311,904,600.

According to the company, this total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca, a global, science-led biopharmaceutical company, is focussed on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular, Renal and Metabolism and Respiratory.